Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 2.320 +0.130 (+5.94%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Lexaria Bioscience Corp < Previous 1 2 3 4 5 6 7 8 9 ... 29 30 Next > Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments November 07, 2024 Via ACCESSWIRE Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study October 24, 2024 DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups Via TheNewswire.com Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study October 24, 2024 Via ACCESSWIRE Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study October 22, 2024 DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups Via TheNewswire.com Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study October 22, 2024 Via ACCESSWIRE Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules October 16, 2024 Kelowna, British Columbia – October 16, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced... Via TheNewswire.com Topics Regulatory Compliance Exposures Legal Regulatory Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing October 09, 2024 Via ACCESSWIRE Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 September 27, 2024 Via ACCESSWIRE Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules October 16, 2024 Via ACCESSWIRE Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules October 15, 2024 Via ACCESSWIRE InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide October 09, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Update on Growth of GLP-1 Market Space, Notes Potential for Oral Delivery October 08, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Welcomes Industry Veteran as New CEO September 05, 2024 Via ACCESSWIRE Lexaria Updates Current GLP-1 Market October 08, 2024 Via ACCESSWIRE HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Strengthen Executive Team in Anticipation of ‘Strong Growth’ into 2025 October 01, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Appoints Michael Shankman as Chief Financial Officer October 01, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide September 27, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide September 27, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs September 20, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations September 20, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations September 20, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study September 17, 2024 Via Investor Brand Network TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program September 13, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO September 06, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO September 06, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO September 05, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study September 05, 2024 Via Investor Brand Network Lexaria Releases Strategic Letter from the Outgoing CEO September 05, 2024 Via ACCESSWIRE TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting September 03, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Enters a Material Transfer Agreement for DehydraTECH Research September 03, 2024 Via ACCESSWIRE < Previous 1 2 3 4 5 6 7 8 9 ... 29 30 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
